



Serotypes, Antibiotic Resistance Genes, and *Salmonella* Pathogenicity Island Genes of *Salmonella* from Patients in a Hospital in Weifang, China

Jie Ma ¹, Weiping Li ², Jing Liu ¹ and Min Li ^{1,*}

¹Department of Clinical Laboratory, Weifang People's Hospital, Weifang, China

²Department of Pediatrics, Weifang People's Hospital, Weifang, China

*Corresponding author: Department of Clinical Laboratory, Weifang People's Hospital, Weifang, China. Email: jyklimin@126.com

Received 2022 June 01; Revised 2022 August 14; Accepted 2022 August 17.

Abstract

Background: *Salmonella* is an important foodborne pathogen that causes diarrhea in humans worldwide.

Objectives: This study aimed to determine the serotype distribution, antibiotic-resistant genes, and *Salmonella* pathogenicity island (SPI) genes of clinical isolates of *Salmonella* in Weifang.

Methods: A total of 111 *Salmonella* strains were collected from Weifang People's Hospital between 2018 and 2020 and subjected to serotyping using the Kauffmann-White antigen table. Meanwhile, the polymerase chain reaction detected eleven SPI-6 genes and six antibiotic resistance genes.

Results: Among the 111 *Salmonella* strains, 17 serotypes were identified, with *S. Typhimurium*, *S. Typhi*, and *S. Enteritidis* being the most prevalent. The *hila*, *ssaB*, *sseC*, *marT*, *siiE*, *pipB*, *sopB*, and *pagN* SPI-6 genes were all found during analysis. The *InvA*, *misL*, and *siiD* genes were detected at 98.2, 97.30, and 97.30% rates, respectively. Also, *sul2* and *bla*_{TEM} were the most prevalent antibiotic resistance genes in this investigation, accounting for 68.47 and 21.62% of the total, respectively.

Conclusions: *Salmonella* isolated from the clinical samples was found to have a diversity of serotypes and possessed various SPI and antibiotic resistance genes.

Keywords: *Salmonella*, Serotype, *Salmonella* Pathogenicity Island (SPI), Antibiotic Resistance Gene

1. Background

Salmonella is a dominant genus of *Enterobacteriaceae* and a foodborne pathogen that can cause food poisoning (1). *Salmonella* is widely distributed in the environment in variable serotypes. There are more than 20 serotypes known to cause zoonosis. About 70 to 80% of the reported food poisoning cases in China are caused by *Salmonella* (2). Currently, three generations of cephalosporins and quinolones are mainly used in the clinical treatment of *Salmonella* infection. With the increase in use time and frequency, many drug-resistant *Salmonella* isolates have appeared (3). Sulfonamides were the first drugs to be used in veterinary medicine in therapeutic doses (4). Sulfonamides were a high priority of veterinary medicines due to their high potential to reach the environment (5). High sulfonamide concentrations increase the risk of food chain contamination (6).

Currently, the drug resistance mode of *Salmonella* is to several antibiotics at the same time, and multidrug-resistant bacteria exist widely globally (7). Therefore, β -lactam resistance genes (*bla*_{TEM}, *bla*_{SHV}, and *bla*_{OXA2}), the sulfonamide resistance gene (*sul2*), and fluoroquinolones resistance genes (*qnrA* and *qnrB*) were selected in this experiment. Studying bacterial antibiotic resistance at the molecular level can help expose the antibiotic resistance mechanism of bacteria. Bacterial pathogenicity is governed by virulence factors. The pathogenicity island aims to investigate these gene clusters, closely associated with bacterial pathogenicity and virulence factors (8). The *Salmonella* pathogenicity island (SPI) encodes virulence factors found throughout the *Salmonella* genome, where SPI-6 is a pathogenic island in *Salmonella*. However, distribution of SPI-6 genes varies between serotypes (9), although SPI-6 is an essential pathogenicity island (10). Con-

sequently, the analysis of the SPI gene may prove helpful in comprehending the pathogenicity and virulence factors of bacteria.

2. Objectives

Analyzing and studying the prevalence, serotype, antibiotic resistance gene, and SPI-6 gene distribution of *Salmonella* in Weifang People's Hospital can help understand the molecular epidemiological characteristics of *Salmonella*, guide clinical rational antibiotic use, and provide data support and a theoretical foundation for disease prevention and control.

3. Methods

3.1. Bacterial Isolates

The study was performed on a collection of clinically identified strains of *Salmonella* from Weifang People's Hospital between 2018 and 2020. The duplicated strains of the same patient at the same site during hospitalization were excluded. The VITEK 2-Compact system (BioMerieux, France) was used to identify the bacteria in all strains.

3.2. Serotype Profiling

The strains were inoculated onto the plate and incubated overnight at 37°C. The O and H antigens of the strains were detected according to the instructions of the *Salmonella* serum diagnostic kit and compared with the Kauffmann-White antigen table to determine the serotype of *Salmonella*.

3.3. Genome DNA Extraction

All strains were streaked onto Luria Bertani agar plates (Oxford, UK) and incubated at 37°C overnight. A single colony was selected for DNA extraction, and total genomic DNA was obtained from *Salmonella* following the manufacturer's instructions using the EZ-10 Spin Column Bacterial Genomic DNA Miniprep Kit (Bio Basic, Canada).

3.4. Determination of Antibiotic Resistance Genes and SPI-6 Genes

Six pairs of antibiotic-resistant gene and eleven pairs of SPI-6 virulence gene amplification primers were designed based on the gene sequences in GenBank and the literature (5, 11-18). All PCR products were sequenced using primer walking, starting with 3CS and 5CS primers (Table 1). The primers were designed by Sangon Biotechnology Co., Ltd.

(Shanghai, China). PCR parameters were preset at 95°C for 5 min; 35 cycles of 94°C for 30 s, 55°C for 30 s, 72°C for 90 s, and 72°C for 10 min. The amplified products were analyzed by electrophoresis on a 1% agarose gel, and the results were visualized using a gel imaging system.

4. Results

4.1. Isolation and Serotype Profiling of *Salmonella* Strains

In this study, 111 strains of *Salmonella* were selected from Weifang People's Hospital inpatients. A total of 17 serotypes were found. The serotypes were mainly *S. Typhimurium*, *S. Typhi*, and *S. Enteritidis*. The serotype profiles are provided in Table 2.

4.2. Molecular Detection of *Salmonella* Antibiotic Resistance Genes

Three antibiotic classes and six antibiotic resistance genes were amplified from the 111 *Salmonella* strains. The carrying rates of β -lactam resistance genes *bla*_{TEM}, *bla*_{SHV}, and *bla*_{OXA2} were 21.62%, 0.9%, and 0.9%, respectively. The carrying rate of the sulfonamide resistance gene *sul2* was estimated to be 68.47%. In comparison, the *qnrA* band rate of the resistance gene in quinolones-resistant strains was 4.50%, without detection of *qnrB* (Table 3).

The antibiotic resistance genes varied among various serotypes (Figure 1). Among them, only one strain, i.e., *S. Enteritidis*, was found to carry *bla*_{SHV} and *bla*_{OXA2}. The *bla*_{TEM} gene was mainly present in *S. Typhimurium*, *S. Typhi*, and *S. Enteritidis*. Different serotypes of *Salmonella* had higher carrying rates of the *sul2* gene, mainly found in *S. Typhimurium*, *S. Typhi*, *S. Enteritidis*, and *S. Paratyphi B*. Four strains of *S. Enteritidis* and one strain of *S. Typhimurium* carried *qnrA* (Table 4).

4.3. Molecular Detection of *Salmonella* Pathogenicity Island Genes

In the 111 *Salmonella* strains, 11 SPI-6 genes were detected. SPI genes *hilA*, *ssaB*, *sseC*, *marT*, *siiE*, *pipB*, *sopB*, and *pagN* were detected in all *Salmonella* strains. The carrying rates of virulence genes *invA*, *misL*, and *siiD* were estimated to be 98.2%, 97.30%, and 97.30%, respectively (Table 5). The carrying rates of *Salmonella* virulence genes varied among various serotypes (Figure 1). The carrying rate of *invA* in *S. Typhimurium* and *S. Typhi* was found to be 96.88% and 95.83%, respectively, while the carrying rate of *misL* and *siiD* in *S. Enteritidis* was found to be 85% each. All other virulence genes had a carrying rate of 100% (Table 6).

Table 1. Primer Sequences of SPI Gene and Antibiotic Resistance Gene of *Salmonella*

	Genes	Primer Sequence (5'-3')	Length (bp)
SPI-1	<i>hilA</i>	F:GACAGAGCTGGACCACAATAAGACA	312
		R:GAGCGTAATTCATCGCCTAAAC	
	<i>InvA</i>	F: GTG AAA TTA TCG CCA CGT ICG GGCAA	284
		R: TCATCGCACCGTCAAAGGAACC	
SPI-2	<i>ssaB</i>	F:GATATCAGGGCCGAAGGTAAT	294
		R:GCAAGTTAAAGCCAGGTGTTT	
	<i>sseC</i>	F:ATGAATCGAATTCACAGTAA	1445
		R:TTAAGCGCGATAGCCAGCTA	
SPI-3	<i>marT</i>	F:CGTCGTCTCACAAACAACATTC	556
		R:CTGACAAATCAATGCCGTAACC	
	<i>misL</i>	F:CACTGACCTGACGCTGAATAG	946
		R:GACTTGACCACGGGAATGATAG	
SPI-4	<i>siiE</i>	F:TTTTTTGCCGATCAAAATCTGTA	750
		R:TATACTATCATCTTTGCTACCGCT	
	<i>siiD</i>	F:GTCAGGGCGTTATCACTACTAAA	826
		R: TTCACATCGCCAGCATAG	
SPI-5	<i>pipB</i>	F:CCTGTGGTGAGTAAGAAGAAG	599
		R:GTCAGTTAAGTCTGAGCCGAATA	
	<i>sopB</i>	F:TACTAAAAACCAGGAGGCTTTT	1000
		R:CGCCATCTTATTGCGGATTTTA	
SPI-6	<i>pagN</i>	F:TCCAGCTTCAGTACGTTTAG	440
		R:GCCTTTGTGCTGCATATAAG	
β-Lactams	<i>bla_{TEM}</i>	F:TCCGCTCATGAGACAATAACC	931
		R:TGGTCTGACAGTTACCAATGC	
	<i>bla_{OXA2}</i>	F:ATACACTTTTGCACITGATGCAG	478
		R:TGAAAAGATCATCCATCTGTTTG	
	<i>bla_{SHV}</i>	F:TGGTTATGCGTTATATTCCGCC	868
		R:GGTTAGCGTTGCCAGTGCT	
Sulphonamides	<i>sul2</i>	F: GCAGGCGGTAAGCTGA	657
		R: GGCTCGTGTGCGGATG	
Quinolones	<i>qnrA</i>	F:ATTTCACGCCAGGATTG	516
		R:GATCGGCAAAGGTTAGGTCA	
	<i>qnrB</i>	F:GTTGGCGAAAAATTGACAGAA	526
		R:ACTCCGAATTGGTCAGATCG	

Serotype	isolate No.	blaA	blaA	blaB	blaC	blaL	blaT	blaE	blaB	blaN	blaS	blaS	blaS	blaA	blaB
S. Typhimurium	1														
	3														
	4														
	11														
	13														
	15														
	30														
	31														
	32														
	33														
	37														
	38														
	40														
	43														
	47														
51															
52															
57															
58															
67															
75															
82															
90															
97															
99															
100															
103															
104															
106															
108															
110															
112															
S. Typhi	12														
	19														
	22														
	27														
	33														
	55														
	56														
	60														
	61														
	64														
	66														
	69														
	70														
	71														
	74														
81															
83															
84															
88															
89															
96															
98															
101															
109															
111															
S. Enteritidis	2														
	23														
	28														
	34														
	42														
	46														
	48														
	49														
	50														
	68														
	91														
	92														
	93														
	94														
	95														
107															
113															
114															
115															
116															
S. Paratyphi B	24														
	26														
	29														
	36														
	39														
	41														
S. Paratyphi C	44														
	54														
	55														
	25														
	35														
S. Paratyphi A	45														
	79														
S. Dublin	102														
	105														
	76														
S. Liverpool	85														
	16														
S. Javiana	17														
	87														
S. Derby	72														
	73														
S. Gallinarum	86														
	18														
S. Concord	59														
	14														
S. Albandan	9														
	7														
S. Choknessuis	8														
	5														
S. London	21														
	10														
S. Wehvreden	63														
	77														
S. Bovismorbificus	80														
	80														

Figure 1. The distribution of the antibiotic resistance genes and the SPI-6 genes in *Salmonella*

Table 2. Serotype Profiling of *Salmonella*

<i>Salmonella</i> Serotypes	Isolates/Proportions, No. (%)
<i>S. Typhimurium</i>	32 (28.83)
<i>S. Typhi</i>	24 (21.62)
<i>S. Enteritidis</i>	20 (18.02)
<i>S. Paratyphi B</i>	9 (8.12)
<i>S. Paratyphi C</i>	6 (5.41)
<i>S. Paratyphi A</i>	2 (1.80)
<i>S. Dublin</i>	3 (2.70)
<i>S. Liverpool</i>	3 (2.70)
<i>S. Javiana</i>	2 (1.80)
<i>S. Derby</i>	3 (2.70)
<i>S. Gallinarum</i>	1 (0.90)
<i>S. Concord</i>	1 (0.90)
<i>S. Aberdeen</i>	1 (0.90)
<i>S. Choleraesuis</i>	1 (0.90)
<i>S. London</i>	1 (0.90)
<i>S. Bovismorbificans</i>	1 (0.90)
<i>S. Weltevreden</i>	1 (0.90)

Table 3. Antibiotic Resistance Gene Prevalence in *Salmonella*

Antimicrobial Agents, Genes	Gene Prevalence, No. (%Rate)
β-Lactams	
<i>bla</i> _{TEM}	24 (21.62)
<i>bla</i> _{OXA2}	1 (0.9)
<i>bla</i> _{SHV}	1 (0.9)
Sulphonamides	
<i>sul2</i>	76 (68.47)
Quinolones	
<i>qnrA</i>	5 (4.50)
<i>qnrB</i>	0 (0)

5. Discussion

There are currently around 2600 known *Salmonella* serotypes with a complex nature. According to the World Health Organization's global *Salmonella* monitoring system, *S. Enteritidis* and *S. Typhimurium* are the most prevalent bacteria responsible for foodborne disease (19, 20). This study showed that the 111 strains of *Salmonella* presented 17 serotypes, indicating that the serotypes in Chinese hospitals are diverse and abundant, with a major share of *S. Typhimurium*, *S. Typhi*, and *S. Enteritidis*, accounting for 68.47% of them (76/111). Also, *S. Typhimurium*

and *S. Enteritidis* accounted for 28.83 and 18.02% of the serotypes, respectively, close to the rates reported in a previous study by Xu et al. (21). However, *S. Typhi* was undetected in Xu et al.'s study, but in this study, *S. Typhi* accounted for 21.62% of the serotypes. Compared to *Salmonella* serotypes in other regions of China, the proportion of *S. Typhi* in Weifang People's Hospital is higher than the hospitals in other regions (21, 22). It can be concluded that serotypes are different in different regions of China and among patients with severe *Salmonella* infection.

Virulence is the root cause of *Salmonella* infection, elicited by the interaction of several virulence genes. SPI mainly encodes *Salmonella* virulence genes on the chromosome (23). More than 20 types of SPI have been discovered so far. SPI1 is required for *Salmonella* to invade host non-phagocytes (24), and SPI2 primarily regulates *Salmonella* multiplication in phagocytes and epithelial cells. SPI3 and SPI4 aid *Salmonella* survival and adherence to the surface of polarized cells, while SPI5 encodes an effector protein released via the type III secretion system encoded by SPI1 and SPI2 (25). Also, SPI6 encodes type VI secret system-related proteins (26). These virulence factors aid *Salmonella* invasion, reproduction, virulence, and transmission in a complex environment (27).

This study selected virulence genes from SPI1 to SPI6 as target genes for PCR amplification. The carrying rates of *hilA*, *ssaB*, *sseC*, *marT*, *siiE*, *pipB*, *sopB*, and *pagN* were 100%, and the carrying rates of *invA*, *misL*, and *siiD* were found to be 98.2%, 97.30%, and 97.30%, respectively. This study showed that the carrying rate of SPI-6 genes was relatively high. Fabrega and Vila discovered that several virulence genes were involved in the expression. The higher virulence gene carrying rate translates into greater potential pathogenicity of *Salmonella* (28), implying that *Salmonella* harboring in these virulence genes is highly pathogenic.

In this experiment, five of the six drug resistance genes were detected, among which *sul2* and *bla*_{TEM} had the highest detection rates. The *sul* genes are found in plasmids and are associated with ubiquitous and long-known sulfonamide resistance Gram-negative bacteria (29). The detection results of the antibiotic resistance genes of the 111 strains of *Salmonella* revealed that the detection rate of the sulfonamide resistance gene *sul2* was 68.47%, which was similar to the rate reported by Adesiji et al. (30). Due to the high detection rate of *sul2*, sulfonamides should be used with caution to prevent the spread of antibiotic resistance and the formation of multidrug-resistant strains. A very important factor of *Salmonella* β -lactam drug resistance is

Table 4. The Distribution of the Antibiotic Resistance Genes in Different Serotypes of *Salmonella*^a

<i>Salmonella</i> Serotypes	<i>bla</i> _{TEM}	<i>bla</i> _{OXA2}	<i>bla</i> _{SHV}	<i>sul2</i>	<i>qnrA</i>	<i>qnrB</i>
<i>S. Typhimurium</i>	10 (31.25)	0 (0)	0 (0)	27 (84.38)	1 (3.13)	0 (0)
<i>S. Typhi</i>	7 (29.17)	0 (0)	0 (0)	18 (75.00)	0 (0)	0 (0)
<i>S. Enteritidis</i>	3 (15.00)	1 (5)	1 (5)	13 (65.00)	4 (20)	0 (0)
<i>S. Paratyphi B</i>	2 (22.22)	0 (0)	0 (0)	6 (66.67)	0 (0)	0 (0)
<i>S. Paratyphi C</i>	0 (0)	0 (0)	0 (0)	1 (16.67)	0 (0)	0 (0)
<i>S. Paratyphi A</i>	0 (0)	0 (0)	0 (0)	1 (50.00)	0 (0)	0 (0)
<i>S. Dublin</i>	1 (33.33)	0 (0)	0 (0)	2 (66.67)	0 (0)	0 (0)
<i>S. Liverpool</i>	0 (0)	0 (0)	0 (0)	2 (66.67)	0 (0)	0 (0)
<i>S. Javiana</i>	0 (0)	0 (0)	0 (0)	1 (50.00)	0 (0)	0 (0)
<i>S. Derby</i>	0 (0)	0 (0)	0 (0)	1 (33.33)	0 (0)	0 (0)
<i>S. Gallinarum</i>	0 (0)	0 (0)	0 (0)	1 (100)	0 (0)	0 (0)
<i>S. Concord</i>	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
<i>S. Aberdeen</i>	0 (0)	0 (0)	0 (0)	1 (100)	0 (0)	0 (0)
<i>S. Choleraesuis</i>	1 (100)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
<i>S. London</i>	0 (0)	0 (0)	0 (0)	1 (100)	0 (0)	0 (0)
<i>S. Bovismorbificans</i>	0 (0)	0 (0)	0 (0)	1 (100)	0 (0)	0 (0)
<i>S. Weltevreden</i>	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

^a Values are expressed as No. (%rate)

Table 5. SPI-6 Gene Prevalence in *Salmonella*

Pathogenicity Islands, Genes	Gene Prevalence, No. (%Rate)
SPI-1	
<i>hilA</i>	111 (100)
<i>invA</i>	109 (98.20)
SPI-2	
<i>ssaB</i>	111 (100)
<i>sseC</i>	111 (100)
SPI-3	
<i>misL</i>	108 (97.30)
<i>marT</i>	111 (100)
SPI-4	
<i>siiD</i>	108 (97.30)
<i>siiE</i>	111 (100)
SPI-5	
<i>pipB</i>	111 (100)
<i>sopB</i>	111 (100)
SPI-6	
<i>pagN</i>	111 (100)

β -lactamase production. Bacteria producing β -lactamase can make hydrolytic inactivation of β -lactam antibiotics, and common types are *bla*_{TEM}, *bla*_{OXA}, and *bla*_{SHV}. This experiment detected *bla*_{TEM}, *bla*_{SHV}, and *bla*_{OXA2} in *Salmonella*. The detection rate of the *bla*_{TEM} gene was estimated to be 21.62%, close to the values reported by Shitta (31). One strain of *S. Enteritidis* was found to carry *bla*_{SHV} and *bla*_{OXA2}. Thus, these strains have the potential for β -lactam antibiotic resistance. According to the detection of drug resistance genes in this study, *bla*_{TEM} has a high carrying rate of β -lactam antibiotic resistance genes, which should be taken into consideration.

In contrast, five strains of *Salmonella* were resistant to quinolones (the *qnrA* gene) with zero detection rate of *qnrB*, indicating that the resistance rate of *Salmonella* in Weifang People's Hospital to quinolones was low, allowing to prioritize the treatment of *Salmonella* infection. Different serotypes of *Salmonella* have different carrying rates of antibiotic resistance genes. *bla*_{TEM} and *sul2* were the main drug resistance genes detected in *S. Typhimurium*, *S. Typhi*, and *S. Paratyphi B*. Appropriate antibiotics can be chosen based on distinct serotypes, allowing for more effective treatment of *Salmonella* infection.

Table 6. The Distribution of the SPI-6 Genes in Different Serotypes of *Salmonella*^a

<i>Salmonella</i> Serotypes	<i>hilA</i>	<i>invA</i>	<i>ssaB</i>	<i>sseC</i>	<i>misL</i>	<i>marT</i>	<i>sttD</i>	<i>sttE</i>	<i>pipB</i>	<i>sopB</i>	<i>pagN</i>
<i>S. Typhimurium</i>	32 (100)	31 (96.88)	31 (100)	32 (100)	32 (100)	32 (100)	32 (100)	32 (100)	32 (100)	32 (100)	32 (100)
<i>S. Typhi</i>	24 (100)	23 (95.83)	24 (100)	24 (100)	24 (100)	24 (100)	24 (100)	24 (100)	24 (100)	24 (100)	24 (100)
<i>S. Enteritidis</i>	20 (100)	20 (100)	20 (100)	20 (100)	17 (85)	20 (100)	17 (85)	20 (100)	20 (100)	20 (100)	20 (100)
<i>S. Paratyphi B</i>	9 (100)	9 (100)	9 (100)	9 (100)	9 (100)	9 (100)	9 (100)	9 (100)	9 (100)	9 (100)	9 (100)
<i>S. Paratyphi C</i>	6 (100)	6 (100)	6 (100)	6 (100)	6 (100)	6 (100)	6 (100)	6 (100)	6 (100)	6 (100)	6 (100)
<i>S. Paratyphi A</i>	2 (100)	2 (100)	2 (100)	2 (100)	2 (100)	2 (100)	2 (100)	2 (100)	2 (100)	2 (100)	2 (100)
<i>S. Dublin</i>	3 (100)	3 (100)	3 (100)	3 (100)	3 (100)	3 (100)	3 (100)	3 (100)	3 (100)	3 (100)	3 (100)
<i>S. Liverpool</i>	3 (100)	3 (100)	3 (100)	3 (100)	3 (100)	3 (100)	3 (100)	3 (100)	3 (100)	3 (100)	3 (100)
<i>S. Javiana</i>	2 (100)	2 (100)	2 (100)	2 (100)	2 (100)	2 (100)	2 (100)	2 (100)	2 (100)	2 (100)	2 (100)
<i>S. Derby</i>	3 (100)	3 (100)	3 (100)	3 (100)	3 (100)	3 (100)	3 (100)	3 (100)	3 (100)	3 (100)	3 (100)
<i>S. Gallinarum</i>	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)
<i>S. Concord</i>	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)
<i>S. Aberdeen</i>	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)
<i>S. Choleraesuis</i>	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)
<i>S. London</i>	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)
<i>S. Bovismorbificans</i>	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)
<i>S. Weltevreden</i>	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)

^a Values are expressed as No. (%rate)

5.1. Conclusions

The results revealed that *Salmonella* serotypes from Weifang People's Hospital inpatients were widely spread. The detection rate of antibiotic-resistant genes and the carrying rate of SPI-6 genes were high. Our findings necessitate strengthening the investigation of *Salmonella* molecular epidemiology and reducing the emergence of *Salmonella* antibiotic resistance.

Footnotes

Authors' Contribution: M.L. designed the study. J.M. conducted the study, collected the data, and prepared the article. J.M., W.L., and J.L. provided advice and edited the article. All authors approved the final version of the article.

Conflict of Interests: The author(s) declare that there are no conflicts of interest.

Funding/Support: Health Commission of Weifang funded this study. (No. wfwsjk-2020-035)

References

- Foley SL, Zhao S, Walker RD. Comparison of molecular typing methods for the differentiation of *Salmonella* foodborne pathogens.

Foodborne Pathog Dis. 2007;**4**(3):253-76. doi: [10.1089/fpd.2007.0085](https://doi.org/10.1089/fpd.2007.0085). [PubMed: [17883310](https://pubmed.ncbi.nlm.nih.gov/17883310/)].

- Majowicz SE, Musto J, Scallan E, Angulo FJ, Kirk M, O'Brien SJ, et al. The global burden of nontyphoidal *Salmonella* gastroenteritis. *Clin Infect Dis.* 2010;**50**(6):882-9. doi: [10.1086/650733](https://doi.org/10.1086/650733). [PubMed: [20158401](https://pubmed.ncbi.nlm.nih.gov/20158401/)].
- Crump JA, Medalla FM, Joyce KW, Krueger AL, Hoekstra RM, Whitchard JM, et al. Antimicrobial resistance among invasive nontyphoidal *Salmonella enterica* isolates in the United States: National Antimicrobial Resistance Monitoring System, 1996 to 2007. *Antimicrob Agents Chemother.* 2011;**55**(3):1148-54. doi: [10.1128/AAC.01333-10](https://doi.org/10.1128/AAC.01333-10). [PubMed: [21199924](https://pubmed.ncbi.nlm.nih.gov/21199924/)]. [PubMed Central: [PMC3067073](https://pubmed.ncbi.nlm.nih.gov/PMC3067073/)].
- Lees P, Pelligand L, Giraud E, Toutain PL. A history of antimicrobial drugs in animals: Evolution and revolution. *J Vet Pharmacol Ther.* 2021;**44**(2):137-71. doi: [10.1111/jvp.12895](https://doi.org/10.1111/jvp.12895). [PubMed: [32725687](https://pubmed.ncbi.nlm.nih.gov/32725687/)].
- Jiang H, Cheng H, Liang Y, Yu S, Yu T, Fang J, et al. Diverse mobile genetic elements and conjugal transferability of sulfonamide resistance genes (*sul1*, *sul2*, and *sul3*) in *Escherichia coli* isolates from *Penaeus vannamei* and pork from large markets in Zhejiang, China. *Front Microbiol.* 2019;**10**:1787. doi: [10.3389/fmicb.2019.01787](https://doi.org/10.3389/fmicb.2019.01787). [PubMed: [31428076](https://pubmed.ncbi.nlm.nih.gov/31428076/)]. [PubMed Central: [PMC6690019](https://pubmed.ncbi.nlm.nih.gov/PMC6690019/)].
- Nunes OC, Manaia CM, Kolvenbach BA, Corvini PF. Living with sulfonamides: a diverse range of mechanisms observed in bacteria. *Appl Microbiol Biotechnol.* 2020;**104**(24):10389-408. doi: [10.1007/s00253-020-10982-5](https://doi.org/10.1007/s00253-020-10982-5). [PubMed: [33175245](https://pubmed.ncbi.nlm.nih.gov/33175245/)].
- Petrovska L, Mather AE, AbuOun M, Branchu P, Harris SR, Connor T, et al. Microevolution of monophasic *Salmonella typhimurium* during epidemic, United Kingdom, 2005-2010. *Emerg Infect Dis.* 2016;**22**(4):617-24. doi: [10.3201/eid2204.150531](https://doi.org/10.3201/eid2204.150531). [PubMed: [26982594](https://pubmed.ncbi.nlm.nih.gov/26982594/)]. [PubMed Central: [PMC4806966](https://pubmed.ncbi.nlm.nih.gov/PMC4806966/)].

8. Hacker J, Blum-Oehler G, Muhlendorfer I, Tschape H. Pathogenicity islands of virulent bacteria: structure, function and impact on microbial evolution. *Mol Microbiol.* 1997;**23**(6):1089–97. doi: [10.1046/j.1365-2958.1997.3101672.x](https://doi.org/10.1046/j.1365-2958.1997.3101672.x). [PubMed: 9106201].
9. Gonzalez-Escobedo G, Marshall JM, Gunn JS. Chronic and acute infection of the gall bladder by *Salmonella* Typhi: understanding the carrier state. *Nat Rev Microbiol.* 2011;**9**(1):9–14. doi: [10.1038/nrmicro2490](https://doi.org/10.1038/nrmicro2490). [PubMed: 21113180]. [PubMed Central: PMC3255095].
10. Hensel M. Evolution of pathogenicity islands of *Salmonella* enterica. *Int J Med Microbiol.* 2004;**294**(2-3):95–102. doi: [10.1016/j.ijmm.2004.06.025](https://doi.org/10.1016/j.ijmm.2004.06.025). [PubMed: 15493819].
11. Sturenburg E, Kuhn A, Mack D, Laufs R. A novel extended-spectrum beta-lactamase CTX-M-23 with a P167T substitution in the active-site omega loop associated with ceftazidime resistance. *J Antimicrob Chemother.* 2004;**54**(2):406–9. doi: [10.1093/jac/dkh334](https://doi.org/10.1093/jac/dkh334). [PubMed: 15201232].
12. Sonbol FI, Khalil MA, Mohamed AB, Ali SS. Correlation between antibiotic resistance and virulence of *Pseudomonas aeruginosa* clinical isolates. *Turk J Med Sci.* 2015;**45**(3):568–77. doi: [10.3906/sag-1406-58](https://doi.org/10.3906/sag-1406-58). [PubMed: 26281322].
13. Pai H, Lyu S, Lee JH, Kim J, Kwon Y, Kim JW, et al. Survey of extended-spectrum beta-lactamases in clinical isolates of *Escherichia coli* and *Klebsiella pneumoniae*: prevalence of TEM-52 in Korea. *J Clin Microbiol.* 1999;**37**(6):1758–63. doi: [10.1128/JCM.37.6.1758-1763.1999](https://doi.org/10.1128/JCM.37.6.1758-1763.1999). [PubMed: 10325320]. [PubMed Central: PMC84943].
14. Doma AO, Popescu R, Mituletu M, Muntean D, Degi J, Boldea MV, et al. Comparative evaluation of *qnrA*, *qnrB*, and *qnrS* genes in Enterobacteriaceae ciprofloxacin-resistant cases, in swine units and a hospital from Western Romania. *Antibiotics (Basel).* 2020;**9**(10). doi: [10.3390/antibiotics9100698](https://doi.org/10.3390/antibiotics9100698). [PubMed: 33066610]. [PubMed Central: PMC7602382].
15. Yue M, Li X, Liu D, Hu X. Serotypes, antibiotic resistance, and virulence genes of *Salmonella* in children with diarrhea. *Viral Hepat J.* 2020;**34**(12). doi: [10.1002/jcla.23525](https://doi.org/10.1002/jcla.23525).
16. Nikiema MEM, Kakou-Ngazona S, Ky/Ba A, Sylla A, Bako E, Addablah AYA, et al. Characterization of virulence factors of *Salmonella* isolated from human stools and street food in urban areas of Burkina Faso. *BMC Microbiol.* 2021;**21**(1):338. doi: [10.1186/s12866-021-02398-6](https://doi.org/10.1186/s12866-021-02398-6). [PubMed: 34895140]. [PubMed Central: PMC8665542].
17. Wang W, Chen J, Shao X, Huang P, Zha J, Ye Y. Occurrence and antimicrobial resistance of *Salmonella* isolated from retail meats in Anhui, China. *Food Sci Nutr.* 2021;**9**(9):4701–10. doi: [10.1002/fsn3.2266](https://doi.org/10.1002/fsn3.2266). [PubMed: 34531984]. [PubMed Central: PMC8441314].
18. Bhowmick PP, Devegowda D, Ruwandepika HAD, Karunasagar I, Karunasagar I. Presence of *Salmonella* pathogenicity island 2 genes in seafood-associated *Salmonella* serovars and the role of the *sseC* gene in survival of *Salmonella* enterica serovar Weltevreden in epithelial cells. *Microbiology (Reading).* 2011;**157**(Pt 1):160–8. doi: [10.1099/mic.0.043596-0](https://doi.org/10.1099/mic.0.043596-0). [PubMed: 20884689].
19. WHO global Salm-Surv strategic plan 2000-2005. World Health Organization; 2022. Available from: <http://www.who.int/salmsurv/links/en/gssstrategicplanreport.pdf>.
20. WHO global Salm-Surv strategic plan 2006-2010. World Health Organization; 2022. Available from: https://www.who.int/salmsurv/general/documents/GSS_STRATEGICPLAN2006.
21. Xu H, Zhang W, Zhang K, Zhang Y, Wang Z, Zhang W, et al. Characterization of *Salmonella* serotypes prevalent in asymptomatic people and patients. *BMC Infect Dis.* 2021;**21**(1):632. doi: [10.1186/s12879-021-06340-z](https://doi.org/10.1186/s12879-021-06340-z). [PubMed: 34210275]. [PubMed Central: PMC8252320].
22. Shen H, Chen H, Ou Y, Huang T, Chen S, Zhou L, et al. Prevalence, serotypes, and antimicrobial resistance of *Salmonella* isolates from patients with diarrhea in Shenzhen, China. *BMC Microbiol.* 2020;**20**(1):197. doi: [10.1186/s12866-020-01886-5](https://doi.org/10.1186/s12866-020-01886-5). [PubMed: 32631309]. [PubMed Central: PMC7339465].
23. O'Regan E, Quinn T, Frye JG, Pages JM, Porwollik S, Fedorka-Cray PJ, et al. Fitness costs and stability of a high-level ciprofloxacin resistance phenotype in *Salmonella* enterica serotype enteritidis: reduced infectivity associated with decreased expression of *Salmonella* pathogenicity island 1 genes. *Antimicrob Agents Chemother.* 2010;**54**(1):367–74. doi: [10.1128/AAC.00801-09](https://doi.org/10.1128/AAC.00801-09). [PubMed: 19917752]. [PubMed Central: PMC2798541].
24. Lou L, Zhang P, Piao R, Wang Y. *Salmonella* pathogenicity island 1 (SPI-1) and its complex regulatory network. *Front Cell Infect Microbiol.* 2019;**9**:270. doi: [10.3389/fcimb.2019.00270](https://doi.org/10.3389/fcimb.2019.00270). [PubMed: 31428589]. [PubMed Central: PMC6689963].
25. Karasova D, Sebkova A, Havlickova H, Sisak F, Volf J, Faldyna M, et al. Influence of 5 major *Salmonella* pathogenicity islands on NK cell depletion in mice infected with *Salmonella* enterica serovar Enteritidis. *BMC Microbiol.* 2010;**10**:75. doi: [10.1186/1471-2180-10-75](https://doi.org/10.1186/1471-2180-10-75). [PubMed: 20226037]. [PubMed Central: PMC2848020].
26. Amaya FA, Blondel CJ, Barros-Infante MF, Rivera D, Moreno-Switt AI, Santiviago CA, et al. Identification of type VI secretion systems effector proteins that contribute to interbacterial competition in *Salmonella* Dublin. *Front Microbiol.* 2022;**13**:811932. doi: [10.3389/fmicb.2022.811932](https://doi.org/10.3389/fmicb.2022.811932). [PubMed: 35222335]. [PubMed Central: PMC8867033].
27. Kariuki S, Revathi G, Kariuki N, Kiiru J, Mwituria J, Hart CA. Characterisation of community acquired non-typhoidal *Salmonella* from bacteraemia and diarrhoeal infections in children admitted to hospital in Nairobi, Kenya. *BMC Microbiol.* 2006;**6**:101. doi: [10.1186/1471-2180-6-101](https://doi.org/10.1186/1471-2180-6-101). [PubMed: 17173674]. [PubMed Central: PMC1764016].
28. Fabrega A, Vila J. *Salmonella* enterica serovar Typhimurium skills to succeed in the host: virulence and regulation. *Clin Microbiol Rev.* 2013;**26**(2):308–41. doi: [10.1128/CMR.00066-12](https://doi.org/10.1128/CMR.00066-12). [PubMed: 23554419]. [PubMed Central: PMC3623383].
29. Xu F, Min F, Wang J, Luo Y, Huang S, Chen M, et al. Development and evaluation of a Luminex xTAG assay for sulfonamide resistance genes in *Escherichia coli* and *Salmonella* isolates. *Mol Cell Probes.* 2020;**49**:101476. doi: [10.1016/j.mcp.2019.101476](https://doi.org/10.1016/j.mcp.2019.101476). [PubMed: 31678631].
30. Adesiji YO, Deekshit VK, Karunasagar I. Antimicrobial-resistant genes associated with *Salmonella* spp. isolated from human, poultry, and seafood sources. *Food Sci Nutr.* 2014;**2**(4):436–42. doi: [10.1002/fsn3.119](https://doi.org/10.1002/fsn3.119). [PubMed: 25473501]. [PubMed Central: PMC4221842].
31. Shitta G, Makanjuola O, Adefoye O, Olowe OA. Extended Spectrum Beta Lactamase (ESBL), blaTEM, blaSHV and blaCTX-M, resistance genes in community and healthcare associated Gram Negative bacteria from Osun State, Nigeria. *Infect Disord Drug Targets.* 2021;**21**(4):595–602. doi: [10.2174/1871526520999200729181559](https://doi.org/10.2174/1871526520999200729181559). [PubMed: 32729432].